Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease |
| |
Authors: | David Garcí a‐Bernal,Marta Palomo,Carlos M. Martí nez,Jos E. Mill n‐Rivero,Ana I. Garcí a‐Guill n,Miguel Blanquer,Maribel Dí az‐Ricart,Robert Sackstein,Enric Carreras,Jose M. Moraleda |
| |
Affiliation: | David García‐Bernal,Marta Palomo,Carlos M. Martínez,José E. Millán‐Rivero,Ana I. García‐Guillén,Miguel Blanquer,Maribel Díaz‐Ricart,Robert Sackstein,Enric Carreras,Jose M. Moraleda |
| |
Abstract: | Allogeneic hematopoietic stem cell transplantation (allo‐HCT) is an effective therapy for the treatment of high‐risk haematological malignant disorders and other life‐threatening haematological and genetic diseases. Acute graft‐versus‐host disease (aGvHD) remains the most frequent cause of non‐relapse mortality following allo‐HCT and limits its extensive clinical application. Current pharmacologic agents used for prophylaxis and treatment of aGvHD are not uniformly successful and have serious secondary side effects. Therefore, more effective and safe prophylaxis and therapy for aGvHD are an unmet clinical need. Defibrotide is a multi‐target drug successfully employed for prophylaxis and treatment of veno‐occlusive disease/sinusoidal obstruction syndrome. Recent preliminary clinical data have suggested some efficacy of defibrotide in the prevention of aGvHD after allo‐HCT. Using a fully MHC‐mismatched murine model of allo‐HCT, we report here that defibrotide, either in prophylaxis or treatment, is effective in preventing T cell and neutrophil infiltration and aGvHD‐associated tissue injury, thus reducing aGvHD incidence and severity, with significantly improved survival after allo‐HCT. Moreover, we performed in vitro mechanistic studies using human cells revealing that defibrotide inhibits leucocyte‐endothelial interactions by down‐regulating expression of key endothelial adhesion molecules involved in leucocyte trafficking. Together, these findings provide evidence that defibrotide may represent an effective and safe clinical alternative for both prophylaxis and treatment of aGvHD after allo‐HCT, paving the way for new therapeutic approaches. |
| |
Keywords: | acute GvHD defibrotide hematopoietic stem cell transplantation |
|
|